Love Collins, III Joins FNIH as VP of Advancement to Accelerate Biomedical Research

The Foundation for the National Institutes of Health (FNIH) appoints Love Collins, III, as Vice President of Advancement, effective May 13, 2024. Collins will lead efforts to expand the organization's resources and accelerate biomedical research programs.

author-image
Nitish Verma
New Update
Love Collins, III Joins FNIH as VP of Advancement to Accelerate Biomedical Research

Love Collins, III Joins FNIH as VP of Advancement to Accelerate Biomedical Research

The Foundation for the National Institutes of Health (FNIH) has announced the appointment of Love Collins, III, as Vice President of Advancement, effective May 13, 2024. In this role, Collins will serve as the FNIH's chief development officer, leading efforts to expand the organization's resources and accelerate the launch of new collaborative biomedical research programs.

Why this matters: The appointment of Love Collins, III, as VP of Advancement has significant implications for the acceleration of biomedical research, which can lead to breakthroughs in disease treatment and prevention. This development has the potential to impact global health outcomes and improve the lives of millions of people worldwide.

Collins brings over 30 years of experience in both the public and private sectors, with expertise in fundraising, strategic planning, and organizational development. He has successfully raised over $500 million for various nonprofit organizations and has held top leadership roles at institutions such as the University of Tennessee Health Science Center, Van Andel Institute, and Howard University.

Julie Gerberding, MD, MPH, President and CEO of the FNIH, expressed her enthusiasm for Collins joining the team, stating, "We are delighted that Mr. Collins is joining the FNIH team. As our chief development officer, his experience in establishing trustworthy relations with research investors and philanthropists aligns perfectly with our mission and will help catalyze the resources we need to expand the scope and impact of our scientific portfolio."

Collins himself shared his excitement about the new role, saying, "I am honored to be a part of the exceptionally talented team at the FNIH. The FNIH is an amazing organization, and I welcome the chance to help expand its public-private partnerships that tackle the complex health challenges that no single organization can solve on its own. Breakthroughs require resources and trustworthy relationships, and I look forward to contributing to both."

The FNIH, established by Congress in 1990 as a not-for-profit 501(c)(3) charitable organization, supports the mission of the National Institutes of Health (NIH) by building public-private partnerships. These partnerships connect leading biomedical scientists at the NIH with their counterparts in life sciences companies, academia, patient organizations, foundations, and regulatory agencies. The FNIH's collaborative efforts contribute to the development of new therapies, diagnostics, and potential cures, while also advancing global health, equity in care, and the training of the next generation of scientists.

With Collins' appointment as Vice President of Advancement, the FNIH gains a seasoned leader with a proven track record of successful fundraising and strategic development. His expertise and passion for advancing biomedical research align seamlessly with the FNIH's mission, positioning the organization to expand its impact and accelerate the pace of scientific discovery in the years to come.

Key Takeaways

  • Love Collins, III, appointed VP of Advancement at FNIH, effective May 13, 2024.
  • Collins will lead efforts to expand FNIH's resources and accelerate biomedical research programs.
  • He brings 30+ years of experience in fundraising, strategic planning, and organizational development.
  • Collins has raised over $500 million for various nonprofit organizations in his career.
  • FNIH aims to accelerate biomedical research, leading to breakthroughs in disease treatment and prevention.